华蟾素制剂在肿瘤患者的临床使用分析  

Clinical use of cinobufagin preparations in cancer patients

作　　者：周秀丽 刘宝生 马文明[1] 汪琪 王杨[4] 赵世鹏[5] ZHOU Xiuli;LIU Baosheng;MA Wenming;WANG Qi;WANG Yang;ZHAO Shipeng(Department of Clinical Pharmacy,Weifang People’s Hospital,Weifang Shandong 261000,China;Department of Clinical Pharmacy,Weifang Hospital of TCM,Weifang Shandong 261000,China;Qingdao University Medical College,Qingdao Shandong 266071,China;Second Department of Oncology,Weifang Hospital of TCM,Weifang Shandong 261000,China;Department of Respiratory Medicine,Linying County,Weifang Shandong 261000,China)

机构地区：[1]潍坊市人民医院临床药学科,山东潍坊261000 [2]潍坊市中医院临床药学科,山东潍坊261000 [3]青岛大学医学部,山东青岛266071 [4]潍坊市中医院肿瘤二科,山东潍坊261000 [5]临朐县人民医院呼吸内科,山东潍坊261000

出　　处：《中国药物警戒》2024年第7期791-797,共7页Chinese Journal of Pharmacovigilance

基　　金：国家自然科学基金资助项目(82273848);潍坊市卫生健康委员会中医药科研项目(WFZYY2022-4-050);潍坊市卫生健康委员会科研项目(WFWSJK2022279)。

摘　　要：目的分析住院肿瘤患者使用华蟾素制剂的应用特点,为华蟾素制剂的合理使用提供参考。方法采用PASSPharmAssist系统调取潍坊市人民医院2020年1月1日至2023年8月31日使用华蟾素制剂的住院患者数据,使用Excel 2016软件对人口学特征、诊断信息和具体使用情况进行统计分析。结果共纳入463例患者,使用华蟾素制剂629例次,调查发现肿瘤患者中男性[平均年龄(63.00±9.70)岁,57.02%]多于女性[平均年龄(59.11±10.83)岁,42.98%],平均年龄(61.31±10.37)岁,涉及前5位癌症种类为肺癌(44.45%)、结直肠癌(28.94%)、胃癌(9.51%)、食管癌(4.10%)、肝癌(3.02%),华蟾素制剂主要用药方案为联合化疗方案(36.57%),存在与免疫检查点抑制剂、靶向药物、镇痛药物以及放疗等方式联合应用230例,其中77例(33.48%)未出现ADR,119例(51.74%)为一般ADR,34例(14.78%)为严重ADR。临床实际应用中存在剂量过大的情况,用药疗程主要集中在10 d以内。结论华蟾素制剂主要用于肺癌以及消化道癌化疗前和化疗时用药,目前其临床疗效和作用机制需进一步验证和阐明,缺乏用药疗程的统一资料,应警惕剂量过大引发的心脏毒性。Objective To conduct a retrospective study of usage of cinobufagin preparations in hospitalized tumor patients in order to provide reference for rational use of cinobufagin.Method The PASSPharmaAssist system was used to retrieve data of patients from Weifang People’s Hospital who used cinobufagin preparations between 1 January,2020 and 31 August,2023.The demographic data,diagnostic information,and usage were statistically analyzed using Excel 2016 software.Results A total of 463 patients were enrolled,and 629 cases of the use of cinobufagin preparations.The survey found that among tumor patients,males[with an average age of(63.00±9.70)years,accounting for(57.02%)]outnumbered females[with an average age of(59.11±10.83)years,accounting for(42.98%)],with an average age of(61.31±10.37)years.The top five types of cancers involved were lung cancer(44.45%),colorectal cancer(28.94%),gastric cancer(9.51%),esophageal cancer(4.10%),and liver cancer(3.02%),The dominating medication regimens involving cinobufagin were combined chemotherapy(36.57%).In addition,there were cases of combined use with immune checkpoint inhibitors,targeted drugs,analgesics and radiotherapy(230 cases).Among them,77 cases(33.48%)had no ADR,119 cases(51.74%)were general ADR and 34 cases(14.78%)were serious ADR.In clinical practice,there was excessive dosage,and the courses of medication were mostly less than 10 days.Conclusion Cinobufagin is primarily used in the treatment of lung cancer and gastrointestinal cancer,especially before and during chemotherapy.The clinical efficacy and mechanism of action remain to be verified and elucidated,and there is still a lack of consensus on the course of medication.It is necessary to be vigilant against cardiac toxicity caused by excessive doses.

关 键 词：华蟾素 肺癌 结直肠癌 胃癌 食管癌 肝癌 肿瘤 化疗 

分 类 号：R979.1[医药卫生—药品] R994.11[医药卫生—药学]